GlassScriptPhysician profile
Melvin Gonzalez
NPI 1194721167
$4,781.12
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $630 · 2021: $1,014 · 2022: $803 · 2023: $1,134 · 2024: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,188.35 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $1,153.65 | 2019-2024 | Xarelto |
| Amgen INC. | $398.56 | 2020-2023 | Repatha |
| Esperion Therapeutics, INC. | $330.19 | 2020-2021 | |
| Boston Scientific Corporation | $259.07 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $236.53 | 2019 | |
| Edwards Lifesciences Corporation | $151.66 | 2022 | |
| Atricure, INC. | $144.25 | 2023-2024 | |
| Medtronic Vascular, INC. | $129.64 | 2019 | |
| Amarin Pharma, INC. | $125.30 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $99.67 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $85.49 | 2023-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $68.11 | 2022-2024 | Ozempic |
| Pfizer INC. | $66.34 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $61.68 | 2023 | Inpefa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $59.92 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $53.73 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $45.27 | 2022-2023 | Verquvo |
| Abbott Laboratories | $45.09 | 2023 | Mitraclip, Cardiomems |
| Kiniksa Pharmaceuticals, LTD. | $26.26 | 2023 | Arcalyst |
| Chiesi USA, INC. | $20.98 | 2023 | Kengreal, Cleviprex |
| Medtronic, INC. | $16.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.